Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedJul 22, 2020Metformin Hydrochloride Extended-Release Tablets USP 1000 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelLupin Pharmaceuticals Inc. · D-1383-2020Class IITerminatedJul 22, 2020Metformin Hydrochloride Extended-release Tablets USP 500 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelLupin Pharmaceuticals Inc. · D-1382-2020Class IIITerminatedJul 15, 2020TecfideracGMP deviations: one lot of the product was distributed to US Markets despite being rejected during in-process control.Biogen MA Inc. · D-1381-2020Class IITerminatedJul 15, 2020CetrotideDefective Container: Market complaints of missing rubber stoppers from drug vial. Missing rubber stoppers could lead to lack of sterility assurance.EMD Serono, Inc. · D-1379-2020Class IIITerminatedJul 15, 2020Nystatin Oral SuspensionFailed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.VistaPharm, Inc. · D-1378-2020Class IIITerminatedJul 15, 2020Nystatin Oral SuspensionFailed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.VistaPharm, Inc. · D-1377-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1375-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1374-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1373-2020Class IIITerminatedJul 8, 2020ZilrettaTemperature Abuse: Product was stored at room temperature longer than 6 weeks and was inadvertently distributed instead of discardedFlexion Therapeutics, Inc. · D-1376-2020Class IITerminatedJul 8, 2020Metformin HCl Extended Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Preferred Pharmaceuticals, Inc. · D-1364-2020Class ITerminatedJul 8, 2020Minoxidil/Biotin/Spironolactone 1.25/5/25 mg capsuleSuper-potent Drug: This recall has been initiated due to the elevated presence of minoxidil and biotin.MasterPharm LLC · D-1363-2020Class IITerminatedJul 8, 2020Childrens Dimetapp Cold & CoughDefective Delivery System: the dosing cups are missing graduations applicable to certain age groups.Glaxosmithkline Consumer Healthcare Holdings · D-1362-2020Class IITerminatedJul 8, 2020Childrens Robitussin Honey Cough and Chest Congestion DMDefective Delivery System: the dosing cups are missing graduations applicable to certain age groups.Glaxosmithkline Consumer Healthcare Holdings · D-1361-2020Class IITerminatedJul 8, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviation: Potential presence of Nitrosodimethylamine (NDMA) Impurity above the established levels.The Harvard Drug Group · D-1360-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1359-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1358-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1357-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1393-2020Class IIITerminatedJul 1, 2020Nabumetone TabletsLabeling Not Elsewhere Classified: The statement Pharmacist: Dispense with the accompanying Medication Guide was not included on the carton label.American Health Packaging · D-1372-2020Class IITerminatedJul 1, 2020Clozapine Tablets USP tabletPresence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.Aurobindo Pharma USA Inc. · D-1370-2020Class IIITerminatedJul 1, 2020Timolol Maleate Sterile Opthalmic SolutionLabeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP...Rising Pharmaceuticals, Inc. · D-1368-2020Class IIITerminatedJul 1, 2020Timolol Maleate USPLabeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP...Rising Pharmaceuticals, Inc. · D-1367-2020Class IITerminatedJul 1, 2020Time-Cap LabsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelMarksans Pharma Limited · D-1356-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1354-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1353-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1352-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1351-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1350-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1349-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1348-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1347-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1345-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1344-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1343-2020Class IIITerminatedJul 1, 2020Duavee (conjugated estrogens/bazedoxifene) tablets 0.45/20 mgFailed Dissolution SpecificationsPfizer Inc. · D-1342-2020Class IITerminatedJul 1, 2020Aripiprazole TabletsLabeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.Alembic Pharmaceuticals Limited · D-1341-2020Class IITerminatedJul 1, 2020Nystatin CreamSubpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.Crown Laboratories · D-1339-2020Class IITerminatedJul 1, 2020Nystatin CreamSubpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.Crown Laboratories · D-1338-2020Class IITerminatedJul 1, 2020Soft Whisper by Powerstick Dandruff ShampoocGMP Deviations: Soft Whisper Dandruff Shampoo was produced with water that failed USP specifications.A.P. Deauville, LLC · D-1337-2020

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.